Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Opus Genetics, Inc.NASDAQ: IRD
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$254.12M, compared with -$147.19M a year earlier.
Context
- Retained earnings amounted to 380.5% of total assets at the end of Q1 FY2026, up 74.9 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -72.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (188.59M) USD
- Year-over-year change
- -35.7%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (188.59M) | -35.7% |
| FY2024 | 2024-12-31 | (139M) | -70.6% |
| FY2023 | 2023-12-31 | (81.47M) | -14.0% |
| FY2022 | 2022-12-31 | (71.48M) | +20.0% |
| FY2021 | 2021-12-31 | (89.37M) | — |
Retained Earnings vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 retained earnings of -$254.12M is the 3rd highest of the 10 companies compared; the peer median is -$730.69M.
- Its year-over-year change of -72.6% is the lowest of 10, against a peer median of -10.7%.
- Retained earnings amounts to 380.5% of total assets for IRD, versus a peer median of 500.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$148.72M | -26.3% | — | 500.7% | |
| Mar 2026 | -$203.22M | -10.7% | — | 562.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$254.12M | -72.6% | — | 380.5% |
| Mar 2026 | -$467.2M | -32.0% | — | 349.6% | |
| Mar 2026 | -$482.81M | -17.1% | — | 177.4% | |
| Mar 2026 | -$730.69M | -6.9% | — | 364.6% | |
| Mar 2026 | -$992.32M | -5.0% | — | 843.7% | |
| Mar 2026 | -$994.99M | -14.4% | — | 414.7% | |
| Mar 2026 | -$1.83B | -4.9% | — | 3686.1% | |
| Mar 2026 | -$2.14B | +2.9% | — | 1149.6% | |
| Peer median (excluding IRD) | -$730.69M | -10.7% | — | 500.7% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.